TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31187264
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannula at 8 L/min
Study: 31187264
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannula (4, 6, and 8 L/min)
Study: 22341702
Drug: Everolimus (C(0):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (C(0): 50 to 90 ng/ml)
Study: 22341702
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) with low dose of cyclosporine (C(0): 100 to 150 ng/ml)
Study: 21387802
Drug: Transcranial magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial magnetic stimulation (TMS) combined with pharmacotherapy
Study: 21387802
Drug: Standalone pharmacotherapy
Normalized name: sandalore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standalone pharmacotherapy
Study: 15802964
Drug: IFN-alpha and
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha and ribavirin treatment
Study: 7486099
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (IV‐F)
Study: 30922713
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (twice-daily 20-min sessions for 5 days)
Study: 30027479
Drug: New mint-flavored
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New mint-flavored nicotine gum (4 mg)
Study: 30027479
Drug: Original flavor
Normalized name: Rest Easy Night Time Original Flavor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original flavor sugar-free nicotine gum (2 mg)
Study: 30027479
Drug: Original flavor
Normalized name: Rest Easy Night Time Original Flavor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original flavor sugar-free nicotine gum (4 mg)
Study: 27402599
Drug: Nicotine (7mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (7mg nicotine patch and placebo capsule)
Study: 27402599
Drug: Methylphenidate (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (placebo patch and 40mg methylphenidate capsule)
Study: 27402599
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo patch and capsule)
Study: 25175269
Drug: Diquafosol 3.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diquafosol 3.0% ophthalmic solution, 1 drop, 6 times daily for 4 weeks before surgery
Study: 25175269
Drug: Artificial tears,
Normalized name: Artificial Tears, ophthalmic ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears, 6 times daily for 4 weeks before surgery
Study: 15163089
Drug: Thalidomide (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (24 mg/kg/day orally) for 1 month
Study: 2468266
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation chemotherapy of anticancer agents (group B)
Study: 2468266
Drug: Bladder instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder instillation chemotherapy of anticancer agents with OK‐432 intradermal injection (group A)
Study: 31854069
Drug: PEth ≥50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEth ≥50 ng/mL
Study: 29304731
Drug: Volixibat (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volixibat (0.5 mg, 1 mg, 5 mg or 10 mg)
Study: 29911849
Drug: 1% Diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Diclofenac Gel
Study: 19016257
Drug: Antipsychotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic therapy in schizophrenic women
Study: 19016257
Drug: Antipsychotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic therapy in schizophrenic men
Study: 16522907
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) supplementation (3.4 g/d)
Study: 11109978
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of estradiol 50 mg and testosterone 100 mg
Study: 1660011
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) treatment, 1.5 x 10(6) IU subcutaneously three times for the first week followed by 3 x 10(6) IU three times weekly for a further 6 weeks.
Study: 1660011
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, matching placebo injections.
Study: 6175136
Drug: Hydrocortisone cream
Normalized name: Hydrocortisone Cream
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone cream 1% (50 micrograms)
Study: 6175136
Drug: Unguentum cetacei
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguentum cetacei simplex (cold cream) (50 micrograms)
Study: 6175136
Drug: Halcinonide cream
Normalized name: Halcinonide Cream
DrugBank: Halcinonide (DB06786)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halcinonide cream base (rubbing)
Study: 17074108
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg twice daily for 4 weeks
Study: 15001263
Drug: RT preceded
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT preceded by chemotherapy (vincristine, etoposide, carboplatin, cyclophosphamide)
Study: 9216554
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (25 g/day)
Study: 8091242
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy with drugs like 5-fluorouracil (5-FU), mitomycin, doxorubicin, and cisplatin
Study: 8091242
Drug: Single agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agents (5-FU and mitomycin)
Study: 8091242
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-FU with radiation therapy
Study: 29284448
Drug: Experience Sampling
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experience Sampling Method Intervention (ESM-I) consisting of six weeks of ESM combined with weekly feedback regarding the individual's positive affective experiences
Study: 18485172
Drug: 1000 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 micrograms of self-administered vaginal misoprostol
Study: 12930165
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.3 g Cr.kg(‐1) body mass for 5 days, followed by 2.25 g Cr for 9 days)
Study: 1545849
Drug: Erythropoietin (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (36 units per kilogram of body weight three times weekly)
Study: 1545849
Drug: Erythropoietin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (18 units per kilogram three times weekly)
Study: 31965179
Drug: l-Leucine (192
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Leucine (192 mg/kg body mass) administered daily for 10 weeks
Study: 2145645
Drug: Intravenous colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colchicine
Study: 591936
Drug: Marijuana extract
Normalized name: marijuana pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana extract calibrated to 0.3 mg/kg delta‐9‐tetrahydrocannabinol
Study: 25736132
Drug: Laparoscopic assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic assisted rectal cancer resection using ENDO RLC general endoscopic linear cutter and single-use loading unit and circular staplers from REACH medical equipment co.LTD
Study: 23608971
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy initiation
Study: 21762269
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy for 14 days (pantoprazole 20 mg, tetracycline 500 mg, metronidazole 500 mg, bismuth subcitrate 240 mg b.i.d.)
Study: 21762269
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy for 10 days (pantoprazole 20 mg, tetracycline 500 mg, metronidazole 500 mg, bismuth subcitrate 240 mg b.i.d.)
Study: 17767071
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 4 mL/kg
Study: 17767071
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 6-8 mL/kg
Study: 15383198
Drug: Quetiapine (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (median dosage, 200 mg/day)
Study: 15383198
Drug: Risperidone (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (median dosage, 3 mg/day)
Study: 8165628
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g dried ginger
Study: 2901018
Drug: Placebo (hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (hypertonic saline infusion of 1200 ml of 2.5% NaCl)
Study: 26546403
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg lidocaine (Group L)
Study: 26546403
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg MgSO4 (Group M)
Study: 26546403
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg MgSO4 plus 40 mg lidocaine (Group M+L)
Study: 15754197
Drug: Ampicillin-sulbactam prophylaxis
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam prophylaxis (3 g every 6 h for 3 days) plus standard treatment
Study: 12414200
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment by detachable platinum coils
Study: 1919626
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg daily for 2 years)
Study: 29878650
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion continued for 24 hours postpartum
Study: 29878650
Drug: No magnesium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No magnesium sulphate infusion (stopped immediately after delivery)
Study: 25187049
Drug: Relaxation Response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relaxation Response (RR) daily practice
Study: 17347862
Drug: Three sessions
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three sessions of constant low-energy treatment (0.08 mJ/mm(2); 1000 impulses) without local anesthesia
Study: 14608267
Drug: Fructo-oligosaccharides (FOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharides (FOS) and Lactobacillus sporogenes preparation
Study: 1422689
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (orchiectomy + radiotherapy)
Study: 25222702
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) with sequential 17β-estradiol plus oral progesterone
Study: 22769858
Drug: Pre-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment group (FNB with 0.4 mL/kg 0.375% bupivacaine plus 1:200,000 epinephrine after spinal anesthesia but before the operation)
Study: 22769858
Drug: Post-treatment group
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment group (FNB with 0.4 mL/kg 0.375% bupivacaine plus 1:200,000 epinephrine immediately after the operation)
Study: 1773780
Drug: PHT 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT 1,000 mg
Study: 1773780
Drug: CBZ 200
Normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBZ 200 mg
Study: 7102728
Drug: Methylphenidate (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (active medication)
Study: 2567431
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (salbutamol and ipratropium bromide)
Study: 2567431
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of salbutamol nebuliser solution in 2 ml of saline
Study: 31880966
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg
Study: 28493891
Drug: AIDSVAX® B/E
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDSVAX® B/E vaccine
Study: 22128728
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg dose of armodafinil
Study: 15259284
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of estradiol valerate (E2V) plus 2.5 mg of medroxyprogesterone acetate (MPA)
Study: 10914173
Drug: Continued low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continued low-dose aspirin
Study: 10914173
Drug: Stopped low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stopped low-dose aspirin
Study: 28193214
Drug: Routine delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine delivery of oral anticancer therapy
Study: 25909473
Drug: Blueberry supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry supplementation (2 cups of frozen blueberries daily for 6 weeks)
Study: 25437150
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (ICBT) for 12 weeks
Study: 21851929
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (ICBT)
Study: 17639992
Drug: Xinmaitong capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinmaitong capsule (XMT)
Study: 23810027
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement intervention for prescribing antihypertensive medication
Study: 21091792
Drug: Test implant
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implant with a 1.8 mm turned neck (T)
Study: 21091792
Drug: Control implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implant with a 2.8 mm turned neck (C)
Study: 14871913
Drug: CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP levels at or above the 90th percentile (10.6 mg/L)
Study: 11798886
Drug: Methimazole plus
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole plus L‐T(4) 50 microgram/d (Group A)
Study: 11798886
Drug: Methimazole in
Normalized name: methimazole Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole in small dose only (Group B)
Study: 7799828
Drug: Premarin cream
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premarin cream (0.625 mg conjugated oestrogens per gram of cream)
Study: 7799828
Drug: Premarin cream
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premarin cream
Study: 2838151
Drug: Single-dose dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose dactinomycin (45 micrograms/kg)
Study: 2838151
Drug: Other hepatotoxic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other hepatotoxic agents
Study: 28398597
Drug: Ozanimod (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod (1 mg/d and 1.5 mg/d for 28 days)
Study: 28398597
Drug: Ozanimod (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod (first dose)
Study: 28398597
Drug: Ozanimod (dose-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod (dose-escalation regimen)
Study: 12353708
Drug: Rice starch
Normalized name: Rice Starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice starch added to bath water (twice daily for 15 min)
Study: 345484
Drug: Neurolept analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurolept analgesia with topical anaesthesia
Study: 345484
Drug: Anticholinergic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic and topical anaesthesia with diazepam
Study: 27117505
Drug: Best conservative
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best conservative care (personalised hip therapy)
Study: 18693478
Drug: Iron-fortified rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified rice (daily portion of cooked rice 5 days per week for 6 months)
Study: 10488999
Drug: H-wave therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-wave therapy (HWT)
Study: 6151741
Drug: Bopindolol 1
Normalized name: bopindolol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol 1 mg
Study: 2439815
Drug: Bopindolol 2
Normalized name: bopindolol
DrugBank: Bopindolol (DB08807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bopindolol 2 mg
Study: 8335427
Drug: benazepril p.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril p.m. (10 mg)
Study: 28627862
Drug: Wearable devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable devices for upper limb rehabilitation (15 daily sessions at least three times a week for 5 weeks)
Study: 24796057
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intravenous analgesia (analgesia-pumper group)
Study: 20403941
Drug: Alcohol beverage
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol beverage (0.4 g/kg)
Study: 18256140
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg/day (26-h delay)
Study: 24636266
Drug: Procalcitonin-guided antibiotic
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin-guided antibiotic therapy
Study: 28721080
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic therapy
Study: 9609801
Drug: Microgravity (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgravity (0 G head‐to‐foot acceleration)
Study: 7928150
Drug: Breast conserving
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conserving treatment (BCT)
Study: 7928150
Drug: Wide resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide resection with a small dose of radiation
Study: 11449182
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol therapy (TTS) 50 mg/day for 6 months
Study: 19853678
Drug: Risedronate, 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate, 35 mg once weekly (RIS)
Study: 17697972
Drug: BU4 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: BU4 (0.8 mg/kg, over 2 hours 4 times a day)
Study: 7778464
Drug: 6% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate solution (CHO)
Study: 104342
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral amphetamine sulfate
Study: 104342
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of oral anileridine dihydrochloride
Study: 104342
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amphetamine and anileridine
Study: 28814143
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg/d
Study: 19421321
Drug: Glutamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.5 g/kg/d)
Study: 3064191
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment (radiotherapy and chemotherapy)
Study: 26674253
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (DC) 40 g daily
Study: 24092978
Drug: Rivastigmine 18
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine 18 mg patch with domperidone 30 mg (RWD)
Study: 21466595
Drug: Risedronate (RIS)
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate (RIS) 35 mg/week plus calcium 1000 mg/day and vitamin D(3) 800 IU/day
Study: 21466595
Drug: Calcium 1000
Normalized name: RITE AID Calcium 1000mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1000 mg/day and vitamin D(3) 800 IU/day
Study: 10853164
Drug: Epidural corticosteroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural corticosteroid injection (100 mg methylprednisolone in 10 mL bupivacaine 0.25%)
Study: 10853164
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no epidural corticosteroid injection)
Study: 1556404
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg Mg(OH)2
Study: 1556404
Drug: 2,400 mg
Normalized name: pancreatin/lipase/protease/amy 2,400 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,400 mg Mg(OH)2
Study: 1556404
Drug: 3,600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,600 mg Mg(OH)2
Study: 1556404
Drug: Mg(OH)2 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg(OH)2 (all doses)